LEADER 03502nam 2200541 450 001 9910743354903321 005 20220926165900.0 010 $a981-16-7813-8 010 $a981-16-7814-6 010 $a981-16-7814-6 035 $a(MiAaPQ)EBC6885479 035 $a(Au-PeEL)EBL6885479 035 $a(CKB)21167787100041 035 $a(PPN)26082948X 035 $a(EXLCZ)9921167787100041 100 $a20220926d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCompetition law and policy in the Japanese pharmaceutical sector /$fedited by Akira Negishi, Masako Wakui and Naoko Mariyama 210 1$aGateway East, Singapore :$cSpringer,$d[2022] 210 4$dİ2022 215 $a1 online resource (xxi, 245 pages) 225 1 $aKobe University monograph series in social science research 311 08$aPrint version: Negishi, Akira Competition Law and Policy in the Japanese Pharmaceutical Sector Singapore : Springer Singapore Pte. Limited,c2022 9789811678134 320 $aIncludes bibliographical references and index. 327 $aRegulation and Competition in the Pharmaceutical Industry in Japan -- Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Declining Population -- Drug Regulation in Japan -- Collaboration between the Patent System and Pharmaceutical Regulations for Drug-discovery Innovation in Japan -- Corruption and Conflicts of Interest in the Pharmaceutical Market: Regulation of Pharmaceutical Companies Gift-giving Practices -- Antimonopoly Act and Its Application to the Pharmaceutical Industry in Japan -- Horizontal Cooperation and Alliances amongst Pharmaceutical Companies and the Japanese Antimonopoly Act -- Merger Regulations in the Japanese Pharmaceutical Industry -- Pay-for-delay Agreements in Japan -- No Challenge Clauses in the Pharmaceutical Industry in Japan -- Will Authorised Biologics deter Biosimilars? -Utilising JFTCs expertise in drug pricing -- The Pharmaceutical Industry in Japan: A History of Its Development -- Trade Practices in the Japanese Pharmaceutical Market: A Simulation Analysis of Improvement Policies. 330 $a"The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States"--Publisher's description. 410 0$aKobe University monograph series in social science research. 606 $aPharmaceutical industry 606 $aDrugs$xLaw and legislation 606 $aAntitrust law 615 0$aPharmaceutical industry. 615 0$aDrugs$xLaw and legislation. 615 0$aAntitrust law. 676 $a343.520721 702 $aNegishi$b Akira$f1943- 702 $aWakui$b Masako$f1969- 702 $aMariyama$b Naoko 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910743354903321 996 $aCompetition law and policy in the Japanese pharmaceutical sector$93559302 997 $aUNINA